REG - Adv Medical Solutns. - Director/PDMR and PCA Shareholding

Advanced Medical SolutionsAnnouncement

02/04/2024 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB0116Ja&default-theme=true

RNS Number : 0116J  Advanced Medical Solutions Grp PLC  02 April 2024

     2 April 2024

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that it was
notified on 28 March 2024 that on the same day Chris Meredith, who is a
Director and PDMR, had sold 40,500 Ordinary Shares of 5p held on his behalf
held in the name of Platform Securities Nominees Limited ("Nominee"), at a
price of 196.15p per Ordinary Share.

 

On the same day, the Company was also informed that at the same time
Individual Savings Accounts ("ISA's") held in the name of Chris Meredith
purchased 5,160 Ordinary Shares of 5p, ISA's held in the name of Ingrid
Meredith purchased 3,792 Ordinary Shares of 5p, ISA's in the name of Chris
Meredith's PCA's purchased 26,472 Ordinary Shares of 5p and that Lifetime
Individual Savings Accounts ("LISA's") held in the name of Chris Meredith's
PCA's purchased 5,076 Ordinary Shares of 5p, all at a price of 196.2p per
Ordinary Share.

 

The number of shares, and the beneficial ownership of the shares, held by
Chris Meredith, Ingrid Meredith and his PCA's remains unchanged. These
transactions are part of normalised tax planning.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Director
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Sale of 5,160 Ordinary Shares of 5p held in the name of the
     Nominee

     ·        Purchase of 5,160 Ordinary Shares of 5p into ISA's held in
     the name of Chris Meredith
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)                                                  Volume(s)
     Sale of shares from Nominee holding at 196.15p per share  5,160
     Purchase by ISA's at 196.2p per share                     5,160
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume: 5,160

     Aggregated price: 196.15p
 e)  Date of the transaction: 28/03/2024
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 5,160

Aggregated price: 196.15p

e)

Date of the transaction: 28/03/2024

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Director
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Sale of 3,792 Ordinary Shares of 5p held in the name of the
     Nominee

     ·        Purchase of 3,792 Ordinary Shares of 5p into ISA's held in
     the name of Ingrid Meredith
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)                                                  Volume(s)
     Sale of shares from Nominee holding at 196.15p per share  3,792
     Purchase by ISA's at 196.2p per share                     3,792
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume: 3,792

     Aggregated price: 196.15p
 e)  Date of the transaction: 28/03/2024
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 3,792

Aggregated price: 196.15p

e)

Date of the transaction: 28/03/2024

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Director
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Sale of 26,472 Ordinary Shares of 5p held in the name of the
     Nominee

     ·        Purchase of 26,472 Ordinary Shares of 5p into ISA's held in
     the name of Chris Meredith's PCA's
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)                                                  Volume(s)
     Sale of shares from Nominee holding at 196.15p per share  26,472
     Purchase by ISA's at 196.2p per share                     26,472
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume: 26,472

     Aggregated price: 196.15p
 e)  Date of the transaction: 28/03/2024
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 26,472

Aggregated price: 196.15p

e)

Date of the transaction: 28/03/2024

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Director
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Sale of 5,076 Ordinary Shares of 5p held in the name of the
     Nominee

     ·        Purchase of 5,076 Ordinary Shares of 5p into LISA's held in
     the name of Chris Meredith's PCA's
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)                                                  Volume(s)
     Sale of shares from Nominee holding at 196.15p per share  5,076
     Purchase by LISA's at 196.2p per share                    5,076
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume: 5,076

     Aggregated price: 196.15p
 e)  Date of the transaction: 28/03/2024
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 5,076

Aggregated price: 196.15p

e)

Date of the transaction: 28/03/2024

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc            Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                                   Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone           AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)              Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank PLC (Broker)                          Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made five acquisitions:
Sealantis, an Israeli developer of innovative internal sealants; Biomatlante,
a French developer and manufacturer of surgical biomaterials, Raleigh, a
leading UK coater and converter of woundcare and bio-diagnostics materials,
AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish
tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Ireland, Germany, France and Israel.
Established in 1991, the Group has more than 900 employees. For more
information, please see www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBXGDSUSGDGSD